[Chemoprevention of colorectal cancer in inflammatory bowel disease].
The risk of developing colorectal cancer is increased in patients with inflammatory bowel disease. Surveillance colonoscopy has not been shown to prolong survival and rates of interval cancer are reported to be high. Continuing colonic inflammation has been shown to be important in the development of colorectal cancer and therefore anti-inflammatory agents such as the 5-aminosalicylates and immunomodulators have been considered as potential chemopreventive agents. This review focuses on various chemopreventive agents that have been clearly shown to reduce the risk of colorectal adenoma and cancer in the patients with inflammatory bowel disease.
Department of Internal Medicine, Dong-A University College of Medicine, 32 Daesingongwon-ro, Seo-gu, Busan 602-714, Korea.
Sung-hee
SH
Han
Jonghun
J
Lee
D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D018890:Chemoprevention; D015179:Colorectal Neoplasms / Q000150:complications* / Q000517:prevention & control*; D005492:Folic Acid / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D015212:Inflammatory Bowel Diseases / Q000150:complications* / Q000188:drug therapy; D019804:Mesalamine / Q000627:therapeutic use; D014580:Ursodeoxycholic Acid / Q000627:therapeutic use
D000893:Anti-Inflammatory Agents; D007166:Immunosuppressive Agents; D019804:Mesalamine; D014580:Ursodeoxycholic Acid; D005492:Folic Acid